Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Oncopeptides

1.66 SEK-1.42 %9/9 17:29
Less than 1K followers

ONCO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-1.42 %
+3.87 %
-2.97 %
+5.18 %
-65.37 %
-68.30 %
-68.79 %
-94.79 %
-94.24 %

Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.

Read more
Market cap
657.76M SEK
Turnover
1.91M SEK
Revenue
71.12M
EBIT %
-315.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Oncopeptides AB is a Swedish biotech company that, after a long development phase, has successfully developed and commercialized a drug called Pepaxti. This drug is intended for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have...
1/1/2026, 6:25 PM
by Hawkmountdiver
6
Q1 2026 Report is out Oncopeptides Oncopeptalks: Q1 report - Oncopeptides In the latest episode of Oncopeptalks, CEO Sofia Heigis and CFO Henrik Bergentoft comments on the Q1 report and other news presented during the week.
5/19/2026, 9:25 AM
by Hawkmountdiver
2
Q2 is out, a good quarter, and according to Redeye, the company will reach profitability without new share issues. https://www.redeye.se/research/1182339/oncopeptides-q2-initial-take-solid-23-q-q-growth?utm_source=finwire&utm_medium=RSS
8/27/2026, 8:42 AM
by Hawkmountdiver
0
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5/11
2026

Interim report Q3'26

Press release2026-08-31 16:45

Redeye: Oncopeptides (Q2 Update): Growth Continues, with CEE Region Unlocked

Oncopeptides
Oncopeptides, Audiocast, Q2'26
Webcast2026-08-27 09:00

Oncopeptides, Audiocast, Q2'26

Oncopeptides
Regulatory press release2026-08-27 08:00

Oncopeptides publicerar rapporten för det andra kvartalet 2026

Oncopeptides

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-27 08:00

Oncopeptides publishes Q2 report 2026

Oncopeptides
Press release2026-08-20 08:00

Inbjudan till presentation av rapporten för andra kvartalet 2026

Oncopeptides
Press release2026-08-20 08:00

Invitation to presentation of the Q2 report 2026

Oncopeptides
Press release2026-08-17 10:00

Oncopeptides erhåller listpris för Pepaxti i Slovenien – första milstolpen för expansionen i Central- och Östeuropa

Oncopeptides
Press release2026-08-17 10:00

Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe

Oncopeptides
Regulatory press release2026-06-30 17:30

Antal aktier och röster i Oncopeptides

Oncopeptides
Regulatory press release2026-06-30 17:30

Number of shares and votes in Oncopeptides

Oncopeptides
Press release2026-06-17 13:45

Första patienten rekryterad i Oncopeptides glioblastomstudie

Oncopeptides
Press release2026-06-17 13:45

First patient enrolled in Oncopeptides’ glioblastoma study

Oncopeptides
Press release2026-06-12 12:59

Oncopeptides skickar in ansökan om typ II-variation till EMA för utvidgning av Pepaxtis indikation till behandling i tredje linjen

Oncopeptides
Press release2026-06-12 12:59

Oncopeptides submits Type II variation application to EMA for Pepaxti label expansion into third line treatment

Oncopeptides
Press release2026-06-08 08:30

Första patienten rekryterad i Oncopeptides real-world-studie MARINA i Tyskland

Oncopeptides
Press release2026-06-08 08:30

First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany

Oncopeptides
Press release2026-05-27 08:30

Oncopeptides presenterar kliniska och translationella data om Pepaxti vid EHA 2026 i Stockholm

Oncopeptides
Press release2026-05-27 08:30

Oncopeptides to present clinical and translational data on Pepaxti at EHA 2026 in Stockholm

Oncopeptides
Press release2026-05-26 08:00

Oncopeptides tecknar avtal med Salus för distribution och kommersialisering av Pepaxti i Central- och Östeuropa

Oncopeptides
Press release2026-05-26 08:00

Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe

Oncopeptides